Profiles and clinical management of hepatitis C patients in Spain: disHCovery study
- PMID: 26032999
Profiles and clinical management of hepatitis C patients in Spain: disHCovery study
Erratum in
- Rev Esp Quimioter. 2015 Dec;28(6):330
Abstract
Introduction: To assess the clinical profile and management of patients with hepatitis C (HCV) infection in an observational study in Spanish hospitals.
Methods: The study included an initial cross-sectional phase (study phase I), in which investigators at 48 hospitals from 14 Spanish regions collected data from approximately 20 consecutive patients each (a total of 1,000 patients) to assess the general features of HCV-infected patients of any genotype. During the second phase (study phase II), data from 878 patients that were infected exclusively with genotype 1 HCV were assessed retrospectively. Eight pre-defined clinical profiles were established, in order to assess clinical and previous treatments characteristics.
Results: Among the HCV-infected individuals that were analysed during the first part, HCV genotype 1 was found to be predominant (with a prevalence of 76.6%), prevailing the subtype 1b (69.8%), with other significant groups infected by genotype 3 (12.3%) and 4 (7.4%). In the second part of the study, 44% of the HCV genotype 1-infected patients were at a F3/F4 fibrosis stage. 15.9% had never been treated, and previously unsuccessfully treated patients that were no longer receiving anti-HCV treatment accounted for 50.8% of cases. Individuals with a sustained virologic response (SVR) to previous dual therapies (based on Interferon and Ribavirin) were only 14.5% and patients under treatment during the study accounted for the remaining 18.8%. A total of 713 patients (81.2%) in the second phase were not receiving any type of therapy over the period analysed, mainly due to the anticipation of new anti-HCV drugs (41.8%), SVR achievement (17.8%) and unresponsiveness to therapies available at the time of the study (9.5%).
Conclusions: HCV genotype 1, predominately 1b, is the most prevalent type in Spain. Advanced fibrosis or cirrhosis is frequent in this group, mainly patients not yet cured.
Similar articles
-
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).Lancet Infect Dis. 2015 Apr;15(4):397-404. doi: 10.1016/S1473-3099(15)70050-2. Epub 2015 Mar 13. Lancet Infect Dis. 2015. PMID: 25773757 Clinical Trial.
-
Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.Lancet. 2015 Mar 21;385(9973):1098-106. doi: 10.1016/S0140-6736(14)62483-1. Epub 2015 Feb 4. Lancet. 2015. PMID: 25659285 Clinical Trial.
-
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program.J Viral Hepat. 2015 May;22(5):469-80. doi: 10.1111/jvh.12342. Epub 2014 Oct 14. J Viral Hepat. 2015. PMID: 25311757
-
Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions.World J Gastroenterol. 2019 Aug 7;25(29):3897-3919. doi: 10.3748/wjg.v25.i29.3897. World J Gastroenterol. 2019. PMID: 31413526 Free PMC article. Review.
-
The new era of hepatitis C virus therapy.Saudi J Gastroenterol. 2015 Nov-Dec;21(6):345-54. doi: 10.4103/1319-3767.170947. Saudi J Gastroenterol. 2015. PMID: 26655128 Free PMC article. Review.
Cited by
-
Distribution of the genotype of the Hepatitis C Virus in Cordoba-Spain.Rev Esp Quimioter. 2018 Apr;31(2):164-165. Epub 2018 Apr 2. Rev Esp Quimioter. 2018. PMID: 29616511 Free PMC article. English. No abstract available.
-
Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study.BMJ Open. 2019 Jun 11;9(6):e026726. doi: 10.1136/bmjopen-2018-026726. BMJ Open. 2019. PMID: 31189677 Free PMC article.
-
Efficacy and safety of pegylated interferon α and ribavirin in patients monoinfected with HCV genotype 4.Prz Gastroenterol. 2018;13(1):22-29. doi: 10.5114/pg.2018.74558. Epub 2018 Mar 26. Prz Gastroenterol. 2018. PMID: 29657607 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous